The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

<p>Abstract</p> <p>Background</p> <p>HER2-positive breast cancers exhibit high rates of innate and acquired resistance to trastuzumab (TZ), a HER2-directed antibody used as a first line treatment for this disease. TZ resistance may in part be mediated by frequent co-exp...

Full description

Bibliographic Details
Main Authors: Masin Dana, Kierkels Guido JJ, Kapanen Anita I, Baker Jennifer HE, Franssen Yannick, Wong Ling, Qadir Mohammed A, Weppler Sherry A, Dragowska Wieslawa H, Minchinton Andrew I, Gelmon Karen A, Bally Marcel B
Format: Article
Language:English
Published: BMC 2011-10-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/11/420

Internet

http://www.biomedcentral.com/1471-2407/11/420

Similar Items